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Humoral immunity depends on both rapid and long-
termantibodyproductionagainst invadingpathogens.
This is achieved by the generation of spatially distinct
extrafollicular plasmablast and follicular germinal
center (GC) B cell populations, but the signals that
guide respondingBcells to thesealternative compart-
ments have not been fully elucidated. Here, we show
that expression of the orphan G protein-coupled
receptor Epstein-Barr virus-induced gene 2 (EBI2,
also known as GPR183) by activated B cells was
essential for their movement to extrafollicular sites
and induction of early plasmablast responses. Con-
versely, downregulation of EBI2 enabled B cells to
access the center of follicles and promoted efficient
GCformation.EBI2 thereforeprovidesapreviouslyun-
characterized dimension to B cell migration that is
crucial for coordinating rapid versus long-term anti-
body responses.
INTRODUCTION
Dynamic changes in lymphocyte localization are fundamental to
the rapid and efficient production of protective antibodies. Anti-
body responses are initiated by the relocalization of antigen-
engaged B cells to the B zone-T zone (B-T) boundary where
cognate interactions with T cells drive initial B cell proliferation
(Kelsoe and Zheng, 1993; Okada and Cyster, 2006). Proliferating
B cell blasts subsequently proceed down one of two indepen-
dent pathways of migration and differentiation (Jacob et al.,
1991; Liu et al., 1991). Responding B cells can migrate from
the B-T boundary to extrafollicular areas where they are induced
to rapidly expand and differentiate into plasmablasts and plasma
cells (MacLennan et al., 2003). These transient antibody-secreting
cells provide the most immediate source of antigen-specific anti-
bodies. Alternatively, antigen-engaged B cells can localize in the
central, follicular dendritic cell (FDC)-rich region of the follicle to
form germinal centers (GCs) (MacLennan, 1994). B cells prolifer-
ating in GCs give rise to high-affinity clones and exit the GC as
long-lived plasma cells and memory B cells (Manz et al., 2005;O’Connor et al., 2003). This second GC-dependent pathway of
B cell differentiation provides a sustained source of antibodies
with enhanced antigen neutralization potential and mediates
long-term immunity against reinfection. The early changes in posi-
tioning that recruit responding B cells to either the extrafollicular or
the GC pathway of antibody production are therefore crucial for
coordinating rapid versus long-term humoral responses.
Lymphocyte mobility and homing is modulated by the chemo-
attractant receptor subfamily of G protein-coupled receptors
(GPCRs) (Campbell et al., 2003; Rot and von Andrian, 2004).
B cell migration and position are controlled to a large extent by
the lymphoid chemokines CXCL13, CXCL12, CCL19, and
CCL21 and the regulated expression of their receptors CXCR5,
CXCR4, and CCR7 (Allen et al., 2004; Forster et al., 1996; Forster
et al., 1999; Hargreaves et al., 2001; Nie et al., 2004; Reif et al.,
2002). Homing of B cells to B cell follicles is dependent on their
expression of CXCR5 (Forster et al., 1996), whereas their move-
ment to the B-T boundary after antigen encounter is directed
by the rapid upregulation of CCR7 (Reif et al., 2002). As activated
B cells differentiate into plasma cells, they downregulate CXCR5
and CCR7 and upregulate CXCR4, which is critical for their local-
ization in the splenic red pulp and subsequent accumulation in
the bone marrow (Hargreaves et al., 2001). Expression of
CXCR5 is retained on B cells seeding GCs and, together with
CXCR4, mediates the organization of GCs (Allen et al., 2004).
Although differential expression of these chemokine receptors
on plasma cells and GC B cell plays an important role in the local-
ization of these populations to their distinct microenviroments, it
is unclear whether additional factors contribute to the migration
of activated B cells to extrafollicular sites versus follicular GCs.
In an effort to discover additional GPCRs directing the migra-
tory events of responding B cells, we identified Epstein-Barr virus
(EBV)-induced gene 2 (EBI2) as a promising candidate. The gene
encoding EBI2 (Ebi2, also known as Gpr183) was originally iden-
tified together with Ebi1 (Ccr7) as the most highly upregulated
gene in EBV-infected Burkitt’s lymphoma cells (Birkenbach
et al., 1993). EBI2 was subsequently reported to be most homol-
ogous to members of the lipid and purine GPCR family (Rose-
nkilde et al., 2006; Surgand et al., 2006). Although lacking any
close homology partner in the chemokine receptor family, EBI2
signals through the pertussis-sensitive Gai protein, similarly to
many chemokine receptors (Rosenkilde et al., 2006). This orphan
GPCR is predominantly expressed in lymphoid tissues and highImmunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc. 259
Immunity
EBI2 Controls Position and Fate of Responding B CellsmRNA expression has been observed in naive B cells (Birken-
bach et al., 1993; Rosenkilde et al., 2006). The already high
constitutive expression of Gpr183 present in naive B cells is
further increased by B cell receptor (BCR)-triggered NF-kB acti-
vation, although this upregulation is only transient (Glynne et al.,
2000). In contrast, GC B cell differentiation is associated with the
shut down of Gpr183 expression, which is controlled by the tran-
scriptional repressor Bcl-6 (Shaffer et al., 2000). Despite this
notable pattern of expression linked to B cell differentiation, the
biological function of EBI2 remains undefined.
In this study, we demonstrate a critical role for EBI2 in the
regulation of a T cell-dependent antibody response. We show
that expression of EBI2 by antigen-specific B cells during the
early stages of the response was essential for their normal migra-
tion to extrafollicular areas of the spleen and differentiation into
plasmablasts. On the other hand, downregulation of EBI2 was
found to mediate migration of B cells to the central regions of
the B cell follicle and enabled the efficient generation of
antigen-specific GC B cells. B cells are therefore guided through
secondary lymphoid microenvironments by the modulation of
EBI2 expression during T cell-dependent B cell responses.
This differential migration ultimately directs plasmablast versus
GC B cell differentiation and thus provides a mechanism for
balancing rapid versus long-term antibody responses.
RESULTS
EBI2 Deficiency Does Not Affect Lymphoid Architecture
nor Chemotaxis to Lymphoid Chemokines
To provide insights into the role of EBI2 in B cell responses, we
generated EBI2-deficient mice. Mice lacking the entire EBI2
coding region in all cells (Gpr183/ mice) were generated on
a C57BL/6 genetic background with a standard gene targeting
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Figure 1. EBI2 Is Not Required for Normal
Lymphocyte Organization and B Cell
Responsiveness to Chemokines
(A) Normal splenic architecture of Gpr183/ mice.
Spleen sections were stained to detect B cell folli-
cles (‘‘B,’’ stained with anti-IgD, green), T cell areas
(‘‘T,’’ stained with anti-CD3, red), and marginal
zone B cells (‘‘MZ,’’ stained with anti-IgM, blue).
‘‘RP’’ stands for red pulp. Images were taken at
103 objective magnification.
(B) Normal chemotactic response of naive poly-
clonal Gpr183/ B cells to lymphoid chemokines
CXCL13, CXCL12, and CCL21. Data are represen-
tative of at least three independent experiments,
using cells from a minimum of five different animals
of each type. The number of migrated cells was
normalized to the migration of control CD45.1+
WT splenocytes added to all wells.
approach (Figure S1 available online).
EBI2-deficient mice exhibited normal
viability and gross phenotype as well as
normal numbers of immature, follicular,
marginal zone and peritoneal B1 B cells
and CD4+ and CD8+ T cells (data not
shown). Histological analysis revealed
typical partitioning of B and T cells within the splenic white
pulp and resolution of follicular and marginal zone B cell popula-
tions (Figure 1A). The normal splenic architecture of EBI2-defi-
cient mice contrasts with the disorganization of splenic lympho-
cytes observed in mice lacking either CXCR5 or CCR7 (Forster
et al., 1996; Forster et al., 1999). Thus, not only was EBI2 not
required for the gross organization of lymphocytes in the spleen
but its expression also did not substantially influence the in vivo
chemotactic activities of the primary lymphocyte chemokine
receptors. Accordingly, EBI2-deficient B cells exhibited normal
cell-surface expression of CXCR5, CXCR4, and CCR7 (data
not shown) and normal in vitro migration to their ligands
(CXCL13, CXCL12, and CCL21 respectively) (Figure 1B).
Differential Expression of EBI2 Regulates B Cell
Localization within the Follicle
In the absence of a gross defect in the localization of B cells within
Gpr183/ mice, we postulated that a potential role for EBI2 in
regulating B cell migration might depend on its differential
expression between B cells present within the same physiolog-
ical compartment. To directly test this proposition, we transferred
purified naive B cells from wild-type (WT) and EBI2-deficient mice
into CD45.1 congenic WT mice and assessed their positioning
within recipient spleens after 18–20 hr by immunohistology. In
contrast to the even distribution of donor WT B cells within splenic
B cell areas, EBI2-deficient B cells accumulated in the center of B
cell follicles, colocalizing with CD21+CD35+ follicular dendritic
cells (FDCs) (Figure 2A). Transferred EBI2-deficient B cells ex-
hibited a similar pattern of localization within the follicles of recip-
ient lymph nodes (Figure S2). When GCs were present within
recipient follicles, transferred EBI2-deficient B cells were also at-
tracted toward the FDC network but did not enter GCs and
instead congregated around them (Figure 2B). These data260 Immunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc.
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EBI2 Controls Position and Fate of Responding B Cellsdemonstrate that differential expression of EBI2 among B cells
had a dramatic effect on their migration, with B cells expressing
relatively high amounts of EBI2 localizing to the outer follicle
and those with low EBI2 expression moving toward the central
FDC-rich region. Modulation of EBI2 expression is therefore
a potentially powerful mechanism for relocating B cells to
different microenvironments within secondary lymphoid tissues.
EBI2 Regulates in BCell Responses to TCell-Dependent
Antigen
The best characterized example of modulated EBI2 expression is
over the course of T cell-dependent B cell responses, during
which antigen-engagement results in a transient increase in
Gpr183 expression and subsequent GC B cell differentiation is
associated with Gpr183 downregulation (Glynne et al., 2000;
Shaffer et al., 2000). To determine whether EBI2 may play a role
in such responses, we initially examined the response of
Gpr183/ mice to the classical T cell-dependent antigen sheep
red blood cells (SRBCs). Histological and flow cytometric anal-
ysis revealed that EBI2-deficient mice produced reduced
numbers of IgG1+B220lo extrafollicular plasma cells in response
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Figure 2. EBI2 Controls the Positioning of
Naive B Cells in Follicles
Adoptively transferred naive EBI2-deficient B cells
accumulate in the center of B cell follicles in FDC-
dense areas and around GCs. Purified polyclonal
Gpr183/ or WT B cells were allowed to home in
WT recipient mice for 18–20 hr and were distin-
guished from host B cells with the congenic marker
CD45.2 (cyan). FDCs were detected with anti-
CD21+CD35 (green) and B cell follicles visualized
with anti-IgD (blue). Recipient mice were either naive
(A)orhadbeen immunized6daysprior toBcell trans-
fer with SRBCs (B). The inset shows accumulation of
Gpr183/ B cells around a GC. T, T cell areas; RP,
red pulp. Images were taken at103objective magni-
fication. Representative sections from one of three
similar experiments are shown.
to SRBC immunization (Figures 3A and
3B). In contrast, EBI2 deficiency did not
affect the corresponding GC response
(Figure 3A) nor did it alter in vitro B cell acti-
vation in response to a variety of BCR-
dependent and -independent stimuli (Fig-
ure 3C). Expression of EBI2 was also not
required for normal plasma cell differentia-
tion in vitro (Figure 3D). EBI2 therefore
appears to play a specific and nonredun-
dant role in the in vivo generation of the
extrafollicular plasma cells in response to
T cell-dependent antigen.
Expression of EBI2 by B Cells Is
Required for Generation of Early T
Cell-Dependent Antibody
Responses
To analyze in more detail the EBI2-medi-
ated regulation of early B cell responses,
we bred anti-hen egg lysozyme (HEL) SWHEL immunoglobulin
heavy chain gene-targeted mice onto the Gpr183/ back-
ground (Phan et al., 2003). Adoptive transfer of EBI2-deficient
SWHEL B cells into WT recipients and challenge with a reduced
HEL affinity mutant (HEL23) conjugated to SRBCs (Paus et al.,
2006) allowed direct assessment of the B cell-intrinsic function
of EBI2 in a T cell-dependent antibody response. Analysis of
Gpr183 expression in WT SWHEL B cells confirmed the rapid up-
regulation of Gpr183 after antigen binding and revealed a strong
modulation of the expression of this receptor in differentiating
SWHEL B cells in vivo, including marked downregulation in GC
B cells (Figure 4A) as previously described (Shaffer et al., 2000).
Defects were observed in the response of EBI2-deficient
SWHEL B cells from as early as 2 days after immunization. At
this point a slight delay in the proliferative expansion of EBI2-
deficient relative to WT SWHEL B cells was apparent by compar-
ison of their respective CFSE dilution profiles (Figure 4B). Partly
as a consequence of this, responding EBI2-deficient SWHEL
B cells were detected at reduced frequencies in the spleen of
recipient animals throughout the first 5 days after immunization
(Figure 4C).Immunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc. 261
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Figure 3. EBI2 Plays a Role in B Cell Responses to T Cell-Dependent Antigen In Vivo but Is Not Required for B Cell Activation and Differen-
tiation In Vitro
(A and B) Reduced generation of IgG1+ plasma cells in the spleen of Gpr183/ mice 6 days after immunization with SRBCs.
(A) Staining of spleen sections for detecting IgG1+ cells (red), GCs (anti-GL7, green), and B cell follicles (anti-IgD, blue).
(B) Quantification of IgG1+ plasma cells by flow cytometry. Plasma cells were identified by high cytoplasmic staining for IgG1 and low B220 expression. The
frequency of cells with this phenotype was increased by a factor of >104 in immunized WT mice compared to naive mice, indicating that they had been specifically
induced by immunization. Means ± SEM are shown (n = 3); p < 0.05 (unpaired two-tailed Student’s t test). Data are representative of two similar experiments.
(C and D) Normal in vitro activation, proliferation, and differentiation of EBI2-deficient B cells.
(C) Stimulation of Gpr183/ and WT B cells with BCR-dependent (anti-IgM) and BCR-independent T cell-derived (anti-CD40) and Toll-like receptor-mediated
signals. Overlays of CFSE dilution and CD86 expression profiles of Gpr183/ and WT B cells, gated on live B220+ cells, are shown.
(D) Stimulation of B cells from Gpr183/ Prdm1+/gfp and Prdm1+/gfp reporter mice for detecting the generation of plasma cells. Mean percentages of Blimp-1-
expressing (GFP+) B220lo cells in duplicate B cell cultures with anti-IgM plus IL-4 and IL-5 or LPS are indicated.Phenotypic analysis of responding EBI2-deficient SWHEL B cells
confirmed that the specific defect in T cell-dependent plasmablast
generation identified previously inGpr183/mice (Figures 3A and
3B) could be attributed to the absence of EBI2 from responding B
cells. On day 4.5 after activation, 50%–60% of WT SWHEL B cells
had acquired a phenotype characteristic of plasmablasts, distin-
guished by downregulation of B220, upregulation of CD138, and
the concomitant switch from surface to cytoplasmic immunoglob-
ulin expression (Figure 4D). Among EBI2-deficient SWHEL B cells,
however, the proportion of cells with this phenotype was typically
<20% (Figure 4D) with total plasmablast frequencies being
reduced to 10%–20% of WT (Figure 4E). In contrast, total frequen-
cies of GC B cells (Figure 4F) and early memory B cells (data not
shown) generated from EBI2-deficient SWHEL donor B cells did262 Immunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc.not differ from the WT control. As anticipated from the impaired
generation of early plasmablasts, the serum anti-HEL IgM and
IgG1 concentrations in recipients of EBI2-deficient SWHEL B cells
were only 10%–20% of those in recipients of WT SWHEL B cells
(Figure 4G), particularly during the initial phase of the response
prior to the emergence of plasma cells from GCs. Expression of
EBI2 by responding B cells was therefore specifically required to
ensure efficientgeneration of T cell-dependentextrafollicular plas-
mablasts and the associated early antibody response.
EBI2 Regulates B Cell Migration during Early T
Cell-Dependent Responses
The results obtained thus far indicated that EBI2 regulates both
B cell migration and the generation of the early T cell-dependent
Immunity
EBI2 Controls Position and Fate of Responding B Cellsplasmablast response. To explore whether these two activities
of EBI2 may be linked, we next assessed by histological anal-
ysis the movement of EBI2-deficient SWHEL B cells within the
spleen during the early stages of their response to HEL23-
SRBC. Within 1 day of initial challenge, antigen-stimulated
WT SWHEL B cells were localized along the B-T boundary (Fig-
ure 5, day 1) as a result of CCR7-induced migration (Reif et al.,
2002). Despite normal upregulation of CCR7 (Figure 6A), most
EBI2-deficient SWHEL B cells did not distribute uniformly along
the B-T boundary, with many migrating deep into T cell areas
(Figure 5, day 1).
Defective migration of EBI2-deficient SWHEL B cells became
increasingly evident as the response progressed. By day 3,
many WT SWHEL B cells had moved to lateral poles of B cell folli-
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Figure 4. Expression of EBI2 by B Cells in
the Initial Stages after Activation Is Required
for Generation of Early Antibody Responses
(A) Quantitative PCR analysis of modulation of
Gpr183 expression in sorted WT SWHEL B cells
after in vitro stimulation with HEL23 or in vivo acti-
vation with HEL23 coupled to SRBCs. Fold differ-
ences to naive SWHEL B cells are shown.
(B–F) Defective response of Gpr183/ SWHEL
B cells to immunization with HEL23-SRBCs.
(B) Overlay of CFSE dilution profiles of Gpr183/
and WT SWHEL B cells 2 days after immunization.
Plots are gated on donor-derived (CD45.
2+CD45.1) HEL-binding B cells.
(C) Total frequencies of donor-derived HEL-
binding B cells determined by flow cytometry.
(D) Phenotypic analysis of SWHEL B cells on day 4.5
shows reduced plasmablast (PB) and increased
GC populations. Plots are gated on donor-derived
HEL-binding B cells. ‘‘Mem’’ represents memory.
(E) Total frequencies of SWHEL plasmablasts iden-
tified by flow cytometry on the basis of their
B220loCXCR5lo phenotype.
(F) Total frequency of SWHEL GC B cells on day 4.5
after immunization. Donor derived HEL-binding
GC B cells were determined by flow cytometry
on the basis of their B220hiGL7hi phenotype.
(G) Anti-HEL IgM and IgG1 concentrations in
serum of recipient mice quantified by ELISA.
Means ± SEM are shown (n = 3); levels of statistical
significance are indicated for day 4.5 (*p < 0.05,
**p < 0.01; ns, not significant, unpaired two-tailed
Student’s t test). Data are representative of three
similar experiments.
cles proximal to bridging and interfollicu-
lar regions. This was not evident,
however, in the response of EBI2-defi-
cient SWHEL B cells, which remained
localized in central follicular areas prox-
imal to the T cell zone (Figure 5, day 3).
Responding EBI2-deficient SWHEL B cells
still persisted in this location 12 hr later,
whereas a large fraction of WT SWHEL B
cells had by this time migrated into the
bridging channels and red pulp (Figure 5,
day 3.5). The relative absence of extrafol-
licular EBI2-deficient SWHEL B cells continued until the peak of
the WT extrafollicular plasmablast response on day 4.5, with
EBI2-deficient B cells instead predominantly moving into GCs
(Figure 5, day 4.5). The failure of EBI2-deficient B cells to form
a robust extrafollicular plasmablast response therefore corre-
lated directly with greatly reduced migration of responding B
cells to the bridging channel and red pulp areas in which these
responses occur (MacLennan et al., 2003). Aberrant migration
of responding EBI2-deficient B cells was not the result of
a defect in regulation of chemokine receptor expression, given
that EBI2-deficient SWHEL B cell subpopulations expressed
normal amounts of CXCR5 and CXCR4 (Figure 6B). As was
observed for naive B cells (Figure 2), responding B cells there-
fore required EBI2 in order to move away from the central areaImmunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc. 263
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EBI2 controls plasmablast differentiation primarily by facilitating
the migration of responding B cells to the extrafollicular micro-
environments where this differentiation process is sustained.
Downregulation of EBI2 during B Cell Differentiation
Promotes Efficient GC Responses
The migration of EBI2-deficient naive B cells to the FDC-rich
areas of the central follicle (Figure 2) coupled with the extensive
downregulation of Gpr183 expression associated with GC B cell
differentiation (Shaffer et al., 2000) (Figure 4A) suggested that the
impetus for central follicular localization provided by downregu-
Figure 5. EBI2 Fine-Tunes the Position of
Responding B Cells
Aberrant migration pattern of Gpr183/ SWHEL
B cells at the indicated time points after challenge
HEL23-SRBCs. Immunofluorescent staining of
spleen sections for detecting the localization of
HEL-binding B cells (green) is shown. The
following abbreviations are used: B, B cell follicles
(stained with anti-IgD, blue); T, T cell areas (stained
with anti-CD3, red); BC, bridging channel; and RP,
red pulp. Images were taken at 103 objective
magnification. Representative sections from one
of three similar experiments are shown.
lation of EBI2 on responding B cells is
important for establishing a GC response.
To test this proposition, SWHEL B cells
were engineered to constitutively express
EBI2 by retroviral-mediated gene transfer
into SWHEL hematopoietic stem cells.
Mature, naive SWHEL B cells transduced
with empty or Gpr183-containing vector
(GFP+) were purified by FACS sorting
and challenged with HEL23-SRBC in
adoptive transfer. Whereas the usual
proportion of control SWHEL B cells
acquired a B220hiPNAhi GC phenotype
on day 5, the frequency of GC B cells in
responses from SWHEL B cells that were
unable to downregulate EBI2 was re-
duced to 25% of empty vector controls
(Figure 7A). Histological analysis con-
firmed the smaller size of GCs forming
from SWHEL B cells with constitutive
EBI2 expression (Figure 7B). Instead,
these B cells differentiated en masse
into extrafollicular plasmablasts (Figures
7A and 7B) and thus produced increased
early anti-HEL IgM and IgG1 concentra-
tions in the sera of recipient mice
(Figure 7C). Despite the dramatic shift in
B cell differentiation evident from consti-
tutive EBI2 expression, the overall
numbers of responding B cells were not
affected (Figure 7D). It is evident, there-
fore, that enforced expression of EBI2
drives extrafollicular plasmablast differentiation, whereas its
downregulation facilitates GC B cell differentiation.
DISCUSSION
The early control of extrafollicular versus GC localization of re-
sponding B cells is controlled to a large extent by the activity
of the chemokine receptors CXCR4, CXCR5, and CCR7.
However, CXCR4-deficient plasma cells are not impacted in
their access to extrafollicular sites, and GC clusters form, albeit
with disorganized structure or orientation, in absence of CXCR4-
or CXR5-mediated chemotaxis (Allen et al., 2004; Hargreaves264 Immunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc.
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EBI2 Controls Position and Fate of Responding B Cellset al., 2001). Thus, the existing experimental evidence points
toward the involvement of an additional signal in the organization
of early migratory events in T cell-dependent B cell responses.
Our findings demonstrate that EBI2-driven positioning of B cells
is a critical component of the mechanism that segregates acti-
vated B cells into the extrafollicular versus GC compartments.
First, EBI2-dependent migration of responding B cells toward
the bridging channels was required for the generation of the early
extrafollicular plasmablast response, a process that was greatly
enhanced by enforced expression of EBI2. Furthermore, the
downregulation of EBI2 expression associated with GC B cell
differentiation was sufficient to drive the accumulation of B cells
in the deep FDC-rich regions of the follicle where GCs originate
and enhanced the formation of GC responses. Although it is clear
from the migration pattern of naive EBI2-deficient B cells that
other activation-induced changes are typically required for
B cells to enter GCs, our data indicate that the downregulation
ofGpr183 by Bcl-6 is one of the critical activities of this transcrip-
tion factor in mediating GC B cell differentiation (Shaffer et al.,
2000).
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Figure 6. EBI2 Deficiency Does Not Affect the Regulation of Chemo-
kine Receptor Expression of Responding B Cells
(A) Analysis of CCR7 upregulation on Gpr183/ and WT SWHEL B cells on day
1. Resting levels on non-HEL-binding CD45.2+ B cells are shown as controls.
(B) Unchanged levels of CXCR5 and CXCR4 expression on responding
Gpr183/ and WT SWHEL B cells on day 4.5. Plots are gated on donor-derived
HEL-binding B cells and are representative of at least three mice.EBI2 remains an orphan GPCR and the identity and source of its
ligand are yet to be described. Molecular studies of EBI2 have
suggested that this receptor has constitutive activity, similar to
that observed for many herpesvirus-encoded 7TM receptors
(Benned-Jensen and Rosenkilde, 2008; Rosenkilde et al., 2006).
It is conceivable that heterodimerization of EBI2with other chemo-
kine receptors could positively or negatively regulate their activity
(Levoye et al., 2006). Accordingly, EBI2 deficiency would be ex-
pected to affect the in vitro chemotactic responses of B cells to
chemokines. Such an outcome was not the case as far as tested.
Thus, although our results do not exclude a constitutive receptor
activity, they indicate that the potential agonist-independent
signaling of EBI2 has no detectable impact on the migration of B
cells to chemokines. Nevertheless, it remains possible that EBI2
modulates B cell responsiveness to chemokines when bound to
its ligand. This orphan GPCR therefore is most likely to regulate
B cell localization through a ligand that exhibits a spatially defined
pattern of production. The migratory behavior of both naive and
activated EBI2-deficient B cells indicated that these B cells failed
to be attracted to the periphery of B cell follicles and extrafollicular
regions, suggesting the presence of an agonist in these areas.
Accumulation of B cells and plasma cells in the marginal-zone-
bridging channels has been observed as a result of unbalanced
chemokine responsiveness (Hargreaves et al., 2001; Reif et al.,
2002). Similarly, autoreactive B cell blasts tend to localize to the
red pulp-T zone border (Phan et al., 2003; Seo et al., 2002; William
et al., 2002). The reasons for this homing pattern are unclear and
suggest the existence of an unknown factor driving the lodgment
of cells to this splenic subcompartment. Although our findings
reveal EBI2 as a good candidate for mediating such localization,
the extent of its contribution remains to be defined. Nevertheless,
EBV-infected B cells, which are induced to express high amounts
of EBI2 (Birkenbach et al., 1993), have been reported to migrate to
extrafollicular regions and toavoid GCsduring infectious mononu-
cleosis (Niedobitek et al., 1992), which is in accordance with our
results on EBI2 function.
For this study we have used the intermediate affinity mutant
antigen HEL23 for immunization. However, we have observed
a similar defect in the plasmablast differentiation of EBI2-defi-
cient SWHEL B cells over a 10,000-fold affinity range by using
WT HEL or the low-affinity mutant HEL33 (data not shown).
This indicates that increasing or decreasing BCR signal strength,
which is known to regulate the plasmablast response (Benson
et al., 2007; Paus et al., 2006), does not correct or exacerbate
the defective response of EBI2-deficient B cells. Consistent
with this result, the in vitro activation and proliferation of B cells
was not affected by absence of EBI2, and therefore a contribu-
tion of EBI2 to the signals required for efficient B cell stimulation
is unlikely. Notably, expression of EBI2 was also not required for
normal in vitro plasmablast differentiation. It is still possible,
however, that signals delivered by EBI2 can directly trigger or
regulate gene expression programs that drive plasmablast
differentiation. On the other hand, the guidance of responding
B cells to distinct microenvironments mediated by modulation
of EBI2 expression may subject them to alternative extracellular
milieus that could direct their subsequent lineage commitment.
Thus, EBI2-deficient B cells may predominantly form GC B cells
in vivo because of the fact that they remain in a microenvironment
proximal to the FDC network, in which antigen deposits andImmunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc. 265
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the long-term effectors of humoral immunity. At the same time,
because the factors and myeloid cell populations supporting
maturation and survival of plasmablasts are concentrated
outside of B cell follicles, they are not encountered by most
responding EBI2-deficient B cells (Garcia De Vinuesa et al.,
1999; Mohr et al., 2009). The control of EBI2 expression, via
NF-kB, Bcl-6, or other pathways, therefore plays an important
role in determining the balance between plasmablast and GC
differentiation. In vitro, cytokines such as interleukin (IL)-4, IL-
6, and IL-10 have been shown to modulate Gpr183 expression
A
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Figure 7. Downregulation of EBI2 during B
Cell Differentiation Promotes Efficient GC
Responses
Abnormal response of SWHEL B cells with enforced
EBI2 expression 5 days after immunization with
HEL2X-SRBCs. Constitutive expression of EBI2
was achieved through retroviral-mediated gene
transfer of bone marrow cells.
(A) Phenotypic analysis of SWHEL B cells to shows
reduced GC and increased plasmablast (PB) pop-
ulations. Plots are gated on donor-derived HEL-
binding B cells. ‘‘Mem’’ represents memory.
Mean percentages are indicated; p < 0.01.
(B) Immunofluorescent staining of spleen sections
to detect HEL-binding B cells (green) in GC
structures (indicated with GC). HEL-specific plas-
mablasts can be distinguished by the bright cyto-
plasmic staining (indicated with PB). The following
abbreviations are used: B, B cell follicles (stained
with anti-IgD, blue); T, T cell areas (stained with
anti-CD3, red). Images were taken at 103 objective
magnification.
(C) Anti-HEL IgM and IgG1 concentrations in serum
of recipient mice quantified by ELISA.
(D) Total frequencies of donor-derived HEL-binding
B cells and SWHEL B cells with a GC or plasmablasts
phenotype as distinguished in (A). Means ± SEM
are shown (n = 3); *p < 0.05, **p < 0.01; ns, not signif-
icant (unpaired two-tailed Student’s t test). Data are
representative of two similar experiments.
(Lam et al., 2008; Shaffer et al., 2000). In
contrast, we have only seen minimal
differences in the expression of Gpr183
mRNA in SWHEL B cells stimulated with
HEL antigen of different affinities (data
not shown). Although regulation of EBI2
is an important component of the early
commitment of responding B cells to the
extrafollicular versus GC pathway of differ-
entiation, it is clear that this fundamental
decision in B cell fate is a complex inter-
play of many signals in vivo. However, it
remains possible that abnormal regulation
of EBI2 expression leads to autoimmune
and inflammatory diseases in which the
balance between plasmablast and GC B
cell differentiation is lost.
The importance of EBI2 for B cell func-
tion was first suggested by the dramatic
upregulation of this receptor in EBV-transformed B cells and
further inferred from its regulation in activated and GC B cells (Bir-
kenbach et al., 1993; Glynne et al., 2000; Shaffer et al., 2000). An
involvement of EBI2 in pathology has also been suggested by its
dysregulated expression in B cell-associated autoimmune and
neoplastic diseases (Aalto et al., 2001; Ye et al., 2003). However,
the function of EBI2 and the significance and implications of its
modulation have long awaited clarification. This study provides
evidence for a biological function of EBI2 and indicates that this
receptor provides an extra dimension to B cell migration and
differentiation. Modulation of EBI2 expression is necessary for266 Immunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc.
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EBI2 Controls Position and Fate of Responding B Cellsensuring both the rapid and long-term antibody production that
are required for optimal protection against pathogens. Identifica-
tion of the putative ligand for EBI2 and elucidation of the molecular
mechanisms by which it controls B cell migration and differentia-
tion may prove valuable in designing new vaccine strategies and
potential therapeutics for immune disorders.
EXPERIMENTAL PROCEDURES
Mice
Generation of conditionally EBI2-deficient mice was performed by Ozgene
(Perth, Australia). Gene targeting was performed in C57BL/6 Bruce 4 ES cells
with a targeting construct in which the second exon of Gpr183, which contains
the entire EBI2 coding sequence, was flanked by loxP sites located 208 bp
upstream of the ATG start codon and 554 bp downstream of the TAA stop
codon. A FRT-flanked PGK-Neor cassette was inserted immediately 50 of
the downstream loxP site and contiguous 50 homology (6407 bp) and 30
homology arms (6030 bp) were added (Figure S1A). Chimeric mice established
from the injection of a homologously recombined ES cell clone into BALB/c
blastocysts were bred directly with C57BL/6 ACT:FLPe transgenic mice
(Rodriguez et al., 2000) so that germ-line deletion of the FRT-flanked PGK-
Neor cassette from the targeted allele could be obtained. Germ-line deletion
of exon 2 to generate a null allele of Gpr183 was achieved by subsequent
breeding to C57BL/6 Zp3-CRE transgenic mice (Lewandoski et al., 1997)
(Figure S1A).ACT:FLPe and Zp3-CRE transgenes were removed and homozy-
gous Gpr183/ mice were generated through subsequent backcrossing of
progeny carrying the null allele of Gpr183. Mice were screened by PCR anal-
ysis of tail-tip DNA with the primers 50-TCCCTTTGAACCTGACTTTTG-30
(P1), 50-CTGTCAACCACCAGCAGAAC-30 (P2), and 50-CGTGCACATGTTTT
CAGTGG-30 (P3) as shown in Figure S1. Analysis of bone marrow, thymus,
spleen, lymph nodes, and peritoneal cavity cells did not reveal any defect in
the development of the immune system of Gpr183/ mice. SWHEL mice and
Prdm1+/gfp reporter mice have been described previously (Kallies et al.,
2004; Phan et al., 2003). C57BL/6 and CD45.1 congenic C57BL/6 (B6.SJL/
ptprca) mice were obtained from the Animal Resources Centre (Perth,
Australia). All mice were maintained on a C57BL/6 genetic background and
housed in a specific pathogen-free environment in the Garvan Institute Biolog-
ical Testing Facility. All experimental protocols were approved by the Garvan/
St. Vincent’s Animal Ethics Committee.
Retroviral Transduction of Hematopoietic Stem Cells
The coding sequence of EBI2 was amplified by PCR from C57BL/6 genomic
DNA and inserted into an MSCV2.2-based retroviral vector containing eGFP
as an expression marker downstream of the internal ribosomal entry site
(IRES). Retrovirus-containing supernatant was generated with the Phoenix-E
packaging cell line together with pCL-Eco packaging vector as described
(Swift et al., 2001). Bone marrow cells were extracted from the femur of SWHEL
mice and cultured for 24 hr in RPMI 1640 supplemented with 10% FCS, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in the presence
of 50 ng/ml mSCF, 20 ng/ml IL-3, and 50 ng/ml IL-6 (all from R&D Systems)
before spin-infecting with retroviral supernatants and 4 mg/ml polybrene
(Sigma). After infection, cells were cultured for additional 24 hr and then
used for reconstituting lethally irradiated C57BL/6 recipient mice. Chimeric
mice had frequencies of HEL-binding B cells comparable to SWHEL mice,
with 30%–50% of B cells being transduced, as assessed by GFP expression.
Adoptive Transfers and Immunizations
The adoptive transfer system, mutant HEL23 protein, and its conjugation to
SRBCs have been described in detail previously (Brink et al., 2008; Paus
et al., 2006). In brief, small numbers (3 3 104) of HEL-binding B cells from
spleen of a donor Gpr183/ or WT SWHEL mouse were transferred intrave-
nously into nonirradiated CD45.1 congenic C57BL/6 recipient mice together
with 23 108 HEL23-SRBC. SWHEL donor B cells were identified by flow cytom-
etry on the basis of their CD45.2+CD45.1 phenotype as well as their ability to
bind HEL. Detailed phenotypic analysis of SWHEL B cells on day 5 has indi-
cated that the after subpopulations of B cells can be distinguished on the basis
of the relative expression of B220 and cell-surface BCR (HEL binding): GCB cells (B220hiBCRlo), IgM+ plasmablasts (B220loBCRhi), IgG+ plasmablasts
(B220loBCRlo), and early memory B cells (B220hiBCRhi) (Chan et al., 2009).
For analysis of the positioning of naive B cells, Gpr183/ or WT B cells
were purified by negative depletion with magnetic cell sorting. B cell purity
was 95%–99%. 3x107 B cells were injected intravenously into CD45.1 con-
genic mice and spleens and inguinal lymph nodes of recipient mice were
collected 18-20 hr later.
Quantitative RT-PCR
HEL-binding B cell populations were sorted into Trizol reagent (Invitrogen) and
total RNA was extracted according to the manufacturer’s instructions. First-
strand cDNA was synthesized with Oligo(dT) primers and AMV Reverse Tran-
scriptase (Promega). Quantification of Gpr183 transcripts in the SWHEL popu-
lations was performed with the SYBR Green PCR Master Mix (Invitrogen) and
the Rotor-Gene system (Corbett). Each sample was assessed in duplicates
and the analysis was repeated with a second set of samples. Expression of
GAPDH was used for copy number normalization. The primer pairs used
were as follows: EBI2 forward 50-CAGCTTTACCCACTCGGATA-30, EBI2
reverse 50-AAGAAGCGGTCTATGCTCAA-30, GAPDH forward 50- TGAAGCA
GGCATCTGAGGG-30, and GAPDH reverse 50- CGAAGGTGGAAGAGTGGG
AG-30. Quantification of Gpr183 expression relative to naive SWHEL B cells
was determined with the comparative threshold cycle method.
Flow Cytometry
Splenocytes were prepared, stained for surface molecules, and analyzed on
a FACSCanto (BD Biosciences) as previously described (Phan et al., 2005).
Intracellular staining was performed after fixation with 10% formalin and per-
meabilization with 0.2% polyethylene sorbitan monolaurate. HEL-binding
B cells were detected with 200 ng/ml HEL (Sigma-Aldrich) and purified
HyHEL9 hybridoma supernatant conjugated to Alexa Fluor 647 (Molecular
Probes). The following antibodies and reagents were used for cell staining:
anti-CD184/CXCR4-biotin (2B11; BD Biosciences), anti-CXCR5-biotin (2G8;
BD Biosciences), anti-CCR7-biotin (4B12; eBiosciences), anti-CD138-biotin
(281.2; BD Biosciences), anti-IgG1-biotin (A85-1; BD Biosciences), PNA-biotin
(Vector Laboratories), streptavidin-PE (BD Biosciences), anti-CD86-PE (GL1;
BD Biosciences), anti-CD45.1-PE/Cy7 (A20; eBiosciences), anti-CD45.2-
PerCP/Cy5.5 (104; eBiosciences), anti-GL7-FITC (GL7; BD Biosciences),
and anti-CD45R/B220-Pacific blue (RA3-6B2; BD Biosciences).
ELISA
HyHEL10 anti-HEL Ig isotype standards were produced and serum anti-HEL
IgM and IgG1 concentrations analyzed by ELISA as previously described
(Phan et al., 2003).
Immunofluorescence Microscopy
Spleen or lymph node sections (5–7 mm) were fixed with acetone and blocked
with 30% horse serum. HEL-binding B cells were detected with 100 ng/ml HEL
(Sigma) and then detected with polyclonal rabbit anti-HEL serum and sheep
anti-rabbit IgG-FITC (Chemicon). T cell areas were revealed with biotinylated
anti-CD3 (500A2; eBiosciences) and Alexa Fluor 555-conjugated streptavidin
(Invitrogen), B cell follicles were revealed with anti-IgD-Alexa Fluor 647 (11-
26c.2a; BioLegend), marginal zone B cells were revealed with anti-IgM-FITC
(R6-60.2; BD Biosciences), GC B cells were revealed with anti-GL7-FITC
(GL7; BD Biosciences); FDCs were revealed with anti-CD21/35 (7G6; BD
Biosciences), and IgG1+ cells were revealed with biotinylated anti-IgG1
(A85.1; BD Biosciencies) and Alexa Fluor 555-conjugated streptavidin (Invitro-
gen) as indicated. Adoptively transferred naiveGpr183/ and WT B cells were
distinguished with biotinylated anti-CD45.2 (104; BD Biosciences) and then
with HRP-conjugated streptavidin and TSA-direct Cy3-tyramide (Perki-
nElmer). All images were obtained at 310 objective magnification.
Transwell Migration Assays
Splenocytes from Gpr183/ and WT mice were allowed to transmigrate
across 5 mm transwell filters (Corning Costar Corp) for 3 hr and were enumer-
ated by flow cytometry as described (Allen et al., 2004). Chemokines were
obtained from R&D Systems. Transwell assays were performed in duplicate
for each chemokine concentration and were repeated with cells from
a minimum of five different animals of each type. The number of migrated cellsImmunity 31, 259–269, August 21, 2009 ª2009 Elsevier Inc. 267
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all wells.
In Vitro Cultures
Cell suspensions from spleens or lymph nodes of Gpr183/ and WT mice
were prepared in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine,
1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 10 mM HEPES,
100 U/ml penicillin, 100 mg/ml streptomycin, and 55 mM 2-ME and stimulated
with 10 mg/ml goat anti-mouse IgM (Jackson ImmunoResearch), 5 mg/ml anti-
CD40 mAb (HM40-3; BD Biosciences), or 2.5 mg/ml LPS. CD86 upregulation
on B cells compared to unstimulated cells was analyzed by flow cytometry
24 hr after stimulation. For analysis of proliferation, B cells purified by magnetic
cell sorting were labeled with CFSE prior to culturing (Phan et al., 2003) and cell
division was assessed by flow cytometry after 3 days. For analysis of plasma
cell differentiation, B cells were purified from from Gpr183/ Prdm1+/gfp and
Prdm1+/gfp reporter mice and cultured for 4 days with 10 mg/ml goat anti-
mouse IgM (Jackson ImmunoResearch) plus 10 ng/ml IL-4 and 2 ng/ml IL-5
(Sigma-Aldrich) or 10 mg/ml LPS.
SWHEL splenocytes were stimulated with 500 ng/ml HEL
23 for 1 and 24 hr
before analysis of Gpr183 expression.
Statistical Analysis
Levels of statistical significance between means were calculated by unpaired
two-tailed Student’s t test.
SUPPLEMENTAL DATA
Supplemental Data include two figures and can be found with this article online
at http://www.cell.com/immunity/supplemental/S1074-7613(09)00313-6.
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